These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

365 related articles for article (PubMed ID: 17082468)

  • 21. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans.
    Fagan AM; Mintun MA; Mach RH; Lee SY; Dence CS; Shah AR; LaRossa GN; Spinner ML; Klunk WE; Mathis CA; DeKosky ST; Morris JC; Holtzman DM
    Ann Neurol; 2006 Mar; 59(3):512-9. PubMed ID: 16372280
    [TBL] [Abstract][Full Text] [Related]  

  • 22. IDEAL: a 6-month, double-blind, placebo-controlled study of the first skin patch for Alzheimer disease.
    Winblad B; Grossberg G; Frölich L; Farlow M; Zechner S; Nagel J; Lane R
    Neurology; 2007 Jul; 69(4 Suppl 1):S14-22. PubMed ID: 17646619
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Therapy of Alzheimer disease].
    Kovács T
    Neuropsychopharmacol Hung; 2009 Mar; 11(1):27-33. PubMed ID: 19731816
    [TBL] [Abstract][Full Text] [Related]  

  • 24. 18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer disease.
    Relkin NR; Szabo P; Adamiak B; Burgut T; Monthe C; Lent RW; Younkin S; Younkin L; Schiff R; Weksler ME
    Neurobiol Aging; 2009 Nov; 30(11):1728-36. PubMed ID: 18294736
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Growth hormone secretagogue MK-677: no clinical effect on AD progression in a randomized trial.
    Sevigny JJ; Ryan JM; van Dyck CH; Peng Y; Lines CR; Nessly ML;
    Neurology; 2008 Nov; 71(21):1702-8. PubMed ID: 19015485
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of immunotherapy with bapineuzumab on cerebrospinal fluid biomarker levels in patients with mild to moderate Alzheimer disease.
    Blennow K; Zetterberg H; Rinne JO; Salloway S; Wei J; Black R; Grundman M; Liu E;
    Arch Neurol; 2012 Aug; 69(8):1002-10. PubMed ID: 22473769
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Alzhemed: a potential treatment for Alzheimer's disease.
    Aisen PS; Gauthier S; Vellas B; Briand R; Saumier D; Laurin J; Garceau D
    Curr Alzheimer Res; 2007 Sep; 4(4):473-8. PubMed ID: 17908052
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Atomoxetine augmentation of cholinesterase inhibitor therapy in patients with Alzheimer disease: 6-month, randomized, double-blind, placebo-controlled, parallel-trial study.
    Mohs RC; Shiovitz TM; Tariot PN; Porsteinsson AP; Baker KD; Feldman PD
    Am J Geriatr Psychiatry; 2009 Sep; 17(9):752-9. PubMed ID: 19700948
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Protective effect of rhubarb derivatives on amyloid beta (1-42) peptide-induced apoptosis in IMR-32 cells: a case of nutrigenomic.
    Misiti F; Sampaolese B; Mezzogori D; Orsini F; Pezzotti M; Giardina B; Clementi ME
    Brain Res Bull; 2006 Dec; 71(1-3):29-36. PubMed ID: 17113925
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetics and amyloid plaque targeting ability of a novel peptide-based magnetic resonance contrast agent in wild-type and Alzheimer's disease transgenic mice.
    Kandimalla KK; Wengenack TM; Curran GL; Gilles EJ; Poduslo JF
    J Pharmacol Exp Ther; 2007 Aug; 322(2):541-9. PubMed ID: 17505020
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CSF tau/Abeta42 ratio for increased risk of mild cognitive impairment: a follow-up study.
    Li G; Sokal I; Quinn JF; Leverenz JB; Brodey M; Schellenberg GD; Kaye JA; Raskind MA; Zhang J; Peskind ER; Montine TJ
    Neurology; 2007 Aug; 69(7):631-9. PubMed ID: 17698783
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Continuous CSF drainage in AD: results of a double-blind, randomized, placebo-controlled study.
    Silverberg GD; Mayo M; Saul T; Fellmann J; Carvalho J; McGuire D
    Neurology; 2008 Jul; 71(3):202-9. PubMed ID: 18525029
    [TBL] [Abstract][Full Text] [Related]  

  • 33. White matter lesion severity is associated with reduced cognitive performances in patients with normal CSF Abeta42 levels.
    Stenset V; Hofoss D; Johnsen L; Skinningsrud A; Berstad AE; Negaard A; Reinvang I; Gjerstad L; Fladby T
    Acta Neurol Scand; 2008 Dec; 118(6):373-8. PubMed ID: 18510598
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CSF biomarkers predict rate of cognitive decline in Alzheimer disease.
    Kester MI; van der Vlies AE; Blankenstein MA; Pijnenburg YA; van Elk EJ; Scheltens P; van der Flier WM
    Neurology; 2009 Oct; 73(17):1353-8. PubMed ID: 19858456
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The F(ab)'2 fragment of an Abeta-specific monoclonal antibody reduces Abeta deposits in the brain.
    Tamura Y; Hamajima K; Matsui K; Yanoma S; Narita M; Tajima N; Xin KQ; Klinman D; Okuda K
    Neurobiol Dis; 2005 Nov; 20(2):541-9. PubMed ID: 15908227
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Orally available compound prevents deficits in memory caused by the Alzheimer amyloid-beta oligomers.
    Townsend M; Cleary JP; Mehta T; Hofmeister J; Lesne S; O'Hare E; Walsh DM; Selkoe DJ
    Ann Neurol; 2006 Dec; 60(6):668-76. PubMed ID: 17192927
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Memantine protects rat cortical cultured neurons against beta-amyloid-induced toxicity by attenuating tau phosphorylation.
    Song MS; Rauw G; Baker GB; Kar S
    Eur J Neurosci; 2008 Nov; 28(10):1989-2002. PubMed ID: 19046381
    [TBL] [Abstract][Full Text] [Related]  

  • 38. No association of CSF biomarkers with APOEepsilon4, plaque and tangle burden in definite Alzheimer's disease.
    Engelborghs S; Sleegers K; Cras P; Brouwers N; Serneels S; De Leenheir E; Martin JJ; Vanmechelen E; Van Broeckhoven C; De Deyn PP
    Brain; 2007 Sep; 130(Pt 9):2320-6. PubMed ID: 17586559
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment of acute ischaemic stroke with the low-affinity, use-dependent NMDA antagonist AR-R15896AR. A safety and tolerability study.
    Diener HC; AlKhedr A; Busse O; Hacke W; Zingmark PH; Jonsson N; Basun H;
    J Neurol; 2002 May; 249(5):561-8. PubMed ID: 12021946
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Double-blind, randomized, placebo-controlled pilot study with anapsos in senile dementia: effects on cognition, brain bioelectrical activity and cerebral hemodynamics.
    Alvarez XA; Pichel V; Pérez P; Laredo M; Corzo D; Zas R; Fernández-Novoa L; Sempere JM; Díaz J; Cacabelos R
    Methods Find Exp Clin Pharmacol; 2000 Sep; 22(7):585-94. PubMed ID: 11196347
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.